Conference Description

October 21, 2006
Park Hyatt Philadelphia
Broad and Walnut Streets
Philadelphia, Pennsylvania 19102
215-893-1234

Tell a friend about this conference

Download the brochure for this conference

See how attendees evaluated this conference

CME Credits: 5.8*

Nonrefundable registration fee: $0.

Target Audience: This conference is for physicians, physician assistants and nurse practitioners.

Program Summary:
The intimate setting of the conference will maximize learning and discussion and will enable rheumatologists to learn first hand from thought leaders in their field.

Learning Objectives:
At the conclusion of this program, participants should be able to:

1. discuss research findings regarding osteonecrosis of the jaw
2. compare the safety and efficacy of intraarticular hyaluronan for the osteoarthritis treatment paradigm
3. discuss the advantages and disadvantages in the use of the Cox-2 anti-inflammatory drug versus the traditionals in treating osteoarthritis
4. discuss new concepts in the evaluation and management of the anti-phospholipid syndrome
5. describe current research in the treatment of vasculitis
6. explain the safety and efficacy of new biologic agents in RA with an emphais on B cell and T cell therapy

Agenda:

7:45-8:30 am		Registration, Continental Breakfast and Welcome Kenneth Maurer, MD
8:30-9:20		What Do We Tell Our Patients Taking Bisphophonates Regarding Osteonecrosis of the Jaw? Michael McClung, MD
9:20-10:10		Intra-articular Hyaluronan: Evidence, controversies, and product comparisons Orrin Troum, MD
10:10-10:30		Morning Break
10:30-11:20		Abatacept: When and why? Carlos J. Lozada, MD, FACP, FACR
11:20-12:10		Recent Research on Therapies for Vasculitis Gary Hoffman, MD
12:10-1:00		Lunch
1:10-2:00		Anti-Phospholipid Syndrome: Current thinking on evaluation and management Robert Lahita, MD
2:00-2:50		B-Cell Therapy: Another option for second line therapy in the rheumatic diseases Marc Cohen, MD
2:50-3:10		Afternoon Break
3:10-4:00		Treatment of Osteoarthritis: Challenges, myths and realities Marc Cohen, MD
4:00		Closing Remarks Kenneth Maurer, MD

Faculty:
Marc Cohen, MD
Professor of Medicine
Mayo Medical School
Chairman of Division of Rheumatology
Mayo Clinic Jacksonville

Gary Hoffman, MD, MS
Harold C. Schott Chair of Rheumatic
and Immunologic Diseases
Professor of Medicine
Lerner College of Medicine
Cleveland Clinic Foundation
Cleveland, Ohio

Robert G. Lahita, MD, PhD
Vice-President and Chairman of Medicine
Jersey City Medical Center
Professor of Medicine,
Mount Sinai Medical School

Carlos J. Lozada, MD, FACP, FACR
Associate Professor
Department of Medicine
Division of Rheumatology
University of Miami Miller School of Medicine

Michael McClung, MD
Associate Professor of Medicine
Oregon Health Sciences University
Director, Oregon Osteoporosis Center

Orrin Troum, MD
Clinical Professor of Medicine
Keck School of Medicine
University of Southern California

Program Planning Committee:
Kenneth Maurer, MD
Charles Kahn, MD, FACP, FACR
Wayne Riskin, MD, FACP, FACR

Activity Director: Alan Goodstat, LCSW

*Continuing Education Information
This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Massachusetts Medical School (UMMS) and the National Association for Continuing Education. UMMS is accredited by ACCME to provide continuing medical education for physicians. UMMS designates this continuing medical education activity for 5.8 credit hours in Category I toward the Physicians Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

Under the auspices of the University of Massachusetts Medical School Office of Continuing Education this offering meets the requirements for 7 contact hours, as specified by the Massachusetts Board of Registration in Nursing (244-CMR 5.04). Each nurse should claim only those hours of credit that he/she actually spend in the educational activity.

This program was supported through educational grants from the following companies: Abbott, Bristol-Myers Squibb, Centocor, Pfizer, sanofi-aventis, Smith & Nephew.